{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:05:32Z","timestamp":1785416732486,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00381-023-06200-y","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T09:03:07Z","timestamp":1698742987000},"page":"823-829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients"],"prefix":"10.1007","volume":"40","author":[{"given":"Mengling","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayou","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"6200_CR1","doi-asserted-by":"publisher","unstructured":"Tsai P, Sahin M (2011) Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. Curr Opin Neurol 24(2):106\u2013113.\u00a0https:\/\/doi.org\/10.1097\/WCO.0b013e32834451c4","DOI":"10.1097\/WCO.0b013e32834451c4"},{"key":"6200_CR2","doi-asserted-by":"publisher","unstructured":"Schwartz RA, Fernandez G, Kotulska K et al (2007) Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57(2):189\u2013202.https:\/\/doi.org\/10.1016\/j.jaad.2007.05.004","DOI":"10.1016\/j.jaad.2007.05.004"},{"key":"6200_CR3","doi-asserted-by":"publisher","unstructured":"Volpi A, Sala G, Lesma E et al (2019) Tuberous sclerosis complex: new insights into clinical and therapeutic approach. J Nephrol 32(3):355\u2013363.\u00a0https:\/\/doi.org\/10.1007\/s40620-018-0547-6. Epub 2018 Nov 7","DOI":"10.1007\/s40620-018-0547-6"},{"key":"6200_CR4","doi-asserted-by":"publisher","unstructured":"Jones AC, Shyamsundar MM, Thomas MW et al (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64(5):1305\u20131315.\u00a0https:\/\/doi.org\/10.1086\/302381","DOI":"10.1086\/302381"},{"key":"6200_CR5","doi-asserted-by":"publisher","unstructured":"Tapon N, Ito N, Dickson BJ et al (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105(3):345\u2013355.\u00a0https:\/\/doi.org\/10.1016\/s0092-8674(01)00332-4","DOI":"10.1016\/s0092-8674(01)00332-4"},{"key":"6200_CR6","doi-asserted-by":"publisher","unstructured":"Uysal SP, Sahin M (2020) Tuberous sclerosis: a review of the past, present, and future. Turk J Med Sci 50(SI-2):1665\u20131676.\u00a0https:\/\/doi.org\/10.3906\/sag-2002-133","DOI":"10.3906\/sag-2002-133"},{"key":"6200_CR7","doi-asserted-by":"publisher","unstructured":"Tee AR, Fingar DC Manning BD et al (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99(21):13571\u201313576.\u00a0https:\/\/doi.org\/10.1073\/pnas.202476899","DOI":"10.1073\/pnas.202476899"},{"key":"6200_CR8","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhou X (2020) Research progress of mTOR inhibitors. Eur J Med Chem 208:112820.\u00a0https:\/\/doi.org\/10.1016\/j.ejmech.2020.112820","DOI":"10.1016\/j.ejmech.2020.112820"},{"key":"6200_CR9","doi-asserted-by":"publisher","unstructured":"Mackeigan JP, Krueger DA (2015) Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol 17(12):1550\u20131559.\u00a0https:\/\/doi.org\/10.1093\/neuonc\/nov152","DOI":"10.1093\/neuonc\/nov152"},{"key":"6200_CR10","doi-asserted-by":"publisher","unstructured":"Palavra F, Robalo C, Reis F (2017) Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex. Oxid Med Cell Longev 9820181.\u00a0https:\/\/doi.org\/10.1155\/2017\/9820181","DOI":"10.1155\/2017\/9820181"},{"key":"6200_CR11","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http:\/\/handbook-5-1.cochrane.org\/"},{"key":"6200_CR12","doi-asserted-by":"publisher","unstructured":"Franz DN, Belousova E, Sparagana S et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125\u2013132.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(12)61134-9","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"6200_CR13","doi-asserted-by":"publisher","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869):817\u2013824.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(12)61767-X","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"6200_CR14","doi-asserted-by":"publisher","unstructured":"French JA, Lawson JA, Yapici Z et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10056):2153\u20132163.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(16)31419-2","DOI":"10.1016\/S0140-6736(16)31419-2"},{"key":"6200_CR15","doi-asserted-by":"publisher","unstructured":"Wataya-Kaneda M, Ohno Y, Fujita Y et al (2018) Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol 154(7):781788.\u00a0https:\/\/doi.org\/10.1001\/jamadermatol.2018.1408","DOI":"10.1001\/jamadermatol.2018.1408"},{"key":"6200_CR16","doi-asserted-by":"publisher","unstructured":"Koenig MK, Bell CS, Hebert AA et al (2018) Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol 154(7):773\u2013780.\u00a0https:\/\/doi.org\/10.1001\/jamadermatol.2018.0464","DOI":"10.1001\/jamadermatol.2018.0464"},{"key":"6200_CR17","doi-asserted-by":"publisher","unstructured":"Overwater IE, Rietman AB, Mous SE et al (2019) A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology 93(2):e200\u2013e209.\u00a0https:\/\/doi.org\/10.1212\/WNL.0000000000007749","DOI":"10.1212\/WNL.0000000000007749"},{"key":"6200_CR18","doi-asserted-by":"publisher","unstructured":"Overwater IE, Rietman AB, Bindels-De HK et al (2016) Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology 87(10):1011\u20131018.\u00a0https:\/\/doi.org\/10.1212\/WNL.0000000000003077","DOI":"10.1212\/WNL.0000000000003077"},{"key":"6200_CR19","doi-asserted-by":"publisher","unstructured":"Li M, Zhou Y, Chen C et al (2019) Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis 14(1):39.\u00a0https:\/\/doi.org\/10.1186\/s13023-019-1012-x","DOI":"10.1186\/s13023-019-1012-x"},{"key":"6200_CR20","doi-asserted-by":"publisher","unstructured":"Li S, Takeuchi F, Wang JA et al (2008) Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc Natl Acad Sci USA 105(9):3539\u20133544.\u00a0https:\/\/doi.org\/10.1073\/pnas.0712397105","DOI":"10.1073\/pnas.0712397105"},{"key":"6200_CR21","doi-asserted-by":"publisher","unstructured":"Samanta D (2020) An updated review of tuberous sclerosis complex-associated autism spectrum disorder. Pediatr Neurol 109:4\u201311.\u00a0https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.03.008","DOI":"10.1016\/j.pediatrneurol.2020.03.008"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-023-06200-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-023-06200-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-023-06200-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T11:12:31Z","timestamp":1708686751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-023-06200-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6200"],"URL":"https:\/\/doi.org\/10.1007\/s00381-023-06200-y","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"19 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}